Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 1, 2015, Pages 254-263

  Krisenko, Mariya O ^a   Geahlen, Robert L ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Apoptosis; Epithelial mesenchymal transition; Protein phosphorylation; Signal transduction; Spleen tyrosine kinase; SYK

Indexed keywords

PROTEIN KINASE SYK; TUMOR PROMOTER; TUMOR SUPPRESSOR PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL INTERACTION; CELL MIGRATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; NEOPLASM; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ALTERNATIVE RNA SPLICING; ANIMAL; CELL COMMUNICATION; CELL SURVIVAL; PHYSIOLOGY;

ALTERNATIVE SPLICING; ANIMALS; CARCINOGENESIS; CELL COMMUNICATION; CELL SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84910012931     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.10.022     Document Type: Review

References (124)

1. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353:172-187.
2. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 2009, 21:140-146.
3. Zioncheck T.F., Harrison M.L., Geahlen R.L. Purification and characterization of a protein-tyrosine kinase from bovine thymus. J. Biol. Chem. 1986, 261:15637-15643.
4. Zioncheck T.F., Harrison M.L., Isaacson C., Geahlen R.L. Generation of an active lymphocyte protein-tyrosine kinase by proteolysis. J. Biol. Chem. 1988, 263:19195-19202.
5. Kobayashi T., Nakamura S.-i., Taniguchi T., Yamamura H. Purification and characterization of a cytosolic protein-tyrosine kinase from porcine spleen. Eur. J. Biochem. 1990, 188:535-540.
6. Wu C., Orozco C., Boyer J., Leglise M., Goodale J., Batalov S., Hodge C.L., Haase J., Janes J., Huss J.W., Su A.I. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009, 10:R130.
7. Lal A., Lash A.E., Altschul S.F., Velculescu V., Zhang L., McLendon R.E., Marra M.A., Prange C., Morin P.J., Polyak K., Papadopoulos N., Vogelstein B., Kinzler K.W., Strausberg R.L., Riggins G.J. A public database for gene expression in human cancers. Cancer Res. 1999, 59:5403-5407.
8. Shin G., Kang T.W., Yang S., Baek S.J., Jeong Y.S., Kim S.Y. GENT: gene expression database of normal and tumor tissues. Cancer Informat. 2011, 10:149-157.
9. Mócsai A., Ruland J., Tybulewicz V.L.J. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 2010, 10:387-402.
10. Sada K., Takano T., Yanagi S., Yamamura H. Structure and function of Syk protein-tyrosine kinase. J. Biochem. 2001, 130:177-186.
11. Grädler U., Schwarz D., Dresing V., Musil D., Bomke J., Frech M., Greiner H., Jäkel S., Rysiok T., Müller-Pompalla D., Wegener A. Structural and biophysical characterization of the Syk activation switch. J. Mol. Biol. 2013, 425:309-333.
12. Abram C.L., Lowell C.A. The expanding role for ITAM-based signaling pathways in immune cells. Sci. STKE 2007, 377:re2.
13. Geahlen R.L. Syk and pTyr'd: signaling through the B cell antigen receptor. Biochim. Biophys. Acta 2009, 1793:1115-1127.
14. Heizmann B., Reth M., Infantino S. Syk is a dual-specificity kinase that self-regulates the signal output from the B-cell antigen receptor. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18563-18568.
15. Uckun F.M., Ma H., Zhang J., Ozer Z., Dovat S., Mao C., Ishkhanian R., Goodman P., Qazi S. Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of Ikaros. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:18072-18077.
16. Geahlen R.L. Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol. Sci. 2014, 35:414-422.
17. Yanagi S., Inatome R., Takano T., Yamamura H. Syk expression and novel function in a wide variety of tissues. Biochem. Biophys. Res. Commun. 2001, 288:495-498.
18. Coopman P.J., Mueller S.C. The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. Cancer Lett. 2006, 241:159-173.
19. Blancato J., Graves A., Rashidi B., Moroni M., Tchobe L., Ozdemirli M., Kallakury B., Makambi K.H., Marian C., Mueller S.C. SYK allelic loss and the role of Syk-regulated genes in breast cancer survival. PLoS One 2014, 9:e87610. 10.1371/journal.pone.0087610.
20. Sung Y.M., Xu X., Sun J., Mueller D., Sentissi K., Johnson P., Urbach E., Seillier-Moiseiwitsch F., Johnson M.D., Mueller S.C. Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo. PLoS One 2009, 4:e7445. 10.1371/journal.pone.0007445.
21. Monroe J.G. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat. Rev. Immunol. 2006, 6:283-294.
22. Turner M., Mee P.J., Costello P.S., Williams O., Price A.A., Duddy L.P., Furlong M.T., Geahlen R.L., Tybulewicz V.L.J. Perinatal lethality and a block in the development of B cells in mice lacking the tyrosine kinase p72syk. Nature 1995, 378:298-302.
23. Fallah-Arani F., Schweighoffer E., Vanes L., Tybulewicz V.L.J. Redundant role for Zap70 in B cell development and activation. Eur. J. Immunol. 2008, 38:1721-1733.
24. Lam K.P., Kuhn R., Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997, 90:1073-1083.
25. Schweighoffer E., Vanes L., Nys J., Cantrell D., McCleary S., Smithers N., Tybulewicz V.L.J. The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity 2013, 38:475-488.
26. Young R.M., Hardy I.R., Clarke R.L., Lundy N., Pine P., Turner B.C., Potter T.A., Refaeli Y. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009, 113:2508-2516.
27. Kipps T.J. Immunobiology of chronic lymphocytic leukemia. Curr. Opin. Hematol. 2003, 10:312-318.
28. Chen L., Huynh L., Apgar J., Tang L., Rassenti L., Weiss A., Kipps T.J. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008, 111:2685-2692.
29. Baudot A.D., Jeandel P.Y., Mouska X., Maurer U., Tartare-Deckert S., Raynaud S.D., Cassuto J.P., Ticchioni M., Deckert M. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression. Oncogene 2009, 28:3261-3273.
30. Rickert R.C. New insights into pre-BCR and BCR signaling with relevance to B cell malignancies. Nat. Rev. Immunol. 2013, 12:578-591.
31. Buchner M., Fuchs S., Prinz G., Pfeifer D., Bartholomé K., Burger M., Chevalier N., Vallat L., Timmer J., Gribben J.G., Jumaa H., Veelken H., Dierks C., Zirlik K. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 2009, 69:5424-5432.
32. Gobessi S., Laurenti L., Longo P.G., Carsetti L., Berno V., Sica S., Leone G., Efremov D.G. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009, 23:686-697.
33. Friedberg J.W., Sharman J., Sweetenham J., Johnston P.B., Vose J.M., LaCasce A., Schaefer-Cutillo J., De Vos S., Sinha R., Leonard J.P., Cripe L.D., Gregory S.A., Sterba M.P., Lowe A.M., Levy R., Shipp M.A. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585.
34. Herman S., Barr P., McAuley E., Liu D. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia 2013, 27:1769-1773.
35. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y., Xu W., Shaffer A.L., Wright G., Xiao W., Powell J., Jiang J.-k., Thomas C.J., Rosenwald A., Ott G., Muller-Hermelink H.K., Gascoyne R.D., Connors J.M., Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pierce S.K., Staudt L.M. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
36. Chen L., Monti S., Juszczynski P., Daley J., Chen W., Witzig T.E., Habermann T.M., Kutok J.L., Shipp M.A. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008, 111:2230-2237.
37. Cheng S., Coffey G., Zhang X.H., Shaknovich R., Song Z., Lu P., Pandey A., Melnick A.M., Sinha U., Wang Y.L. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011, 118:6342-6352.
38. Chen L., Monti S., Juszczynski P., Ouyang J., Chapuy B., Neuberg D., Doench J.G., Bogusz A.M., Habermann T.M., Dogan A., Witzig T.E., Kutok J.L., Rodig S.J., Golub T., Shipp M.A. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013, 23:826-838.
39. Juszczynski P., Chen L., O'Donnell E., Polo J.M., Ranuncolo S.M., Dalla-Favera R., Melnick A., Shipp M.A. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood 2009, 114:5315-5321.
40. Chen L., Juszczynski P., Takeyama K., Aguiar R.C.T., Shipp M.A. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood 2006, 108:3428-3433.
41. Leseux L., Hamdi S., Saati T., Capilla F., Recher C., Laurent G., Bezombes C. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006, 108:4156-4162.
42. Rinaldi A., Kwee I., Taborelli M., Largo C., Uccella S., Martin V., Poretti G., Gaidano G., Calabrese G., Martinelli G., Baldini L., Pruneri G., Capella C., Zucca E., Cotter F.E., Cigudosa J.C., Catapano C.V., Tibiletti M.G., Bertoni F. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Haematol. 2006, 132:303-316.
43. Ruiz-Ballesteros E., Mollejo M., Rodriguez A., Camacho F.I., Algara P., Martinez N., Pollán M., Sanchez-Aguilera A., Menarguez J., Campo E., Martinez P., Mateo M., Piris M.A. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005, 106:1831-1838.
44. Irish J., Czerwinski D. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 2006, 108:3135-3142.
45. Arribas A.J., Gómez-Abad C., Sánchez-Beato M., Martinez N., DiLisio L., Casado F., Cruz M.A., Algara P., Piris M.A., Mollejo M. Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. Mod. Pathol. 2013, 26:889-901.
46. Perova T., Grandal I., Nutter L.M.J., Papp E., Matei I.R., Beyene J., Kowalski P.E., Hitzler J.K., Minden M.D., Guidos C.J., Danska J.S. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia. Sci. Transl. Med. 2014, 6:236ra62.
47. Uckun F.M., Ek R.O., Jan S.-T., Chen C.-L., Qazi S. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic. Br. J. Haematol. 2010, 149:508-517.
48. Uckun F.M., Qazi S., Cely I., Sahin K., Shahidzadeh A., Ozercan I., Yin Q., Gaynon P., Termuhlen A., Cheng J., Yiv S. Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. Blood 2013, 121:4348-4354.
49. Feldman A., Sun D., Law M., Novak A. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia 2008, 22:1139-1143.
50. Warner K., Weit N., Crispatzu G., Admirand J., Jones D., Herling M. T-cell receptor signaling in peripheral T-cell lymphoma - a review of patterns of alterations in a central growth regulatory pathway. Curr. Hematol. Malig. Rep. 2013, 8(3):163-172.
51. Merchant M., Caldwell R., Longnecker R. The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J. Virol. 2000, 74:9115-9124.
52. Caldwell R.G., Wilson J.B., Anderson S.J., Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998, 9:405-411.
53. Hatton O., Phillips L.K., Vaysberg M., Hurwich J., Krams S.M., Martinez O.M. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+(EBV+) B cell lymphomas. J. Biol. Chem. 2011, 286:37368-37378.
54. Hahn C.K., Berchuck J.E., Ross K.N., Kakoza R.M., Clauser K., Schinzel A.C., Ross L., Galinsky I., Davis T.N., Silver S.J., Root D.E., Stone R.M., DeAngelo D.J., Carroll M., Hahn W.C., Carr S.A., Golub T.R., Kung A.L., Stegmaier K. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 2009, 16:281-294.
55. Miller P.G., Al-Shahrour F., Hartwell K.A., Chu L.P., Järås M., Puram R.V., Puissant A., Callahan K.P., Ashton J., McConkey M.E., Poveromo L.P., Cowley G.S., Kharas M.G., Labelle M., Shterental S., Fujisaki J., Silberstein L., Alexe G., Al-Hajj M.A., Shelton C.A., Armstrong S.A., Root D.E., Scadden D.T., Hynes R.O., Mukherjee S., Stegmaier K., Jordan C.T., Ebert B.L. In vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell 2013, 24:45-58.
56. 2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. Blood 2013, 121:3889-3899.
57. Mócsai A., Abram C.L., Jakus Z., Hu Y., Lanier L.L., Lowell C.A. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat. Immunol. 2006, 7:1326-1333.
58. Puissant A., Fenouille N., Alexe G., Pikman Y., Bassil C.F., Mehta S., Du J., Kazi J.U., Luciano F., Rönnstrand L., Kung A.L., Aster J.C., Galinsky I., Stone R.M., DeAngelo D.J., Hemann M.T., Stegmaier K. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell 2014, 25:226-242.
59. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., Cerami E., Sander C., Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6:l1.
60. Kuno Y., Abe A., Emi N., Iida M., Yokozawa T., Towatari M., Tanimoto M., Saito H. Constitutive kinase activation of the TEL-Sy k fusion gene in myelodysplastic syndrome with t(9; 12)(q22; p12). Blood 2001, 97:1050-1055.
61. Dierks C., Adrian F., Fisch P., Ma H., Maurer H., Herchenbach D., Forster C.U., Sprissler C., Liu G., Rottmann S., Guo G.-R., Katja Z., Veelken H., Warmuth M. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res. 2010, 70:6193-6204.
62. Pechloff K., Holch J., Ferch U., Schweneker M., Brunner K., Kremer M., Sparwasser T., Quintanilla-Martinez L., Zimber-Strobl U., Streubel B., Gewies A., Peschel C., Ruland J. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J. Exp. Med. 2010, 207:1031-1044.
63. Hussain A., Mohammad D.K., Gustafsson M.O., Uslu M., Hamasy A., Nore B.F., Mohamed A.J., Smith C.I.E. Signaling of the ITK (interleukin 2-inducible T cell kinase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76 and on the adapter function of the kinases SYK and ZAP70. J. Biol. Chem. 2013, 288:7338-7350.
64. Hug E., Hobeika E., Reth M., Jumaa H. Inducible expression of hyperactive Syk in B cells activates Blimp-1-dependent terminal differentiation. Oncogene 2014, 33:3730-3741.
65. Bach M.P., Hug E., Werner M., Holch J., Sprissler C., Pechloff K., Zirlik K., Zeiser R., Dierks C., Ruland J., Jumaa H. Premature terminal differentiation protects from deregulated lymphocyte activation by ITK-Syk. J. Immunol. 2014, 192:1024-1033.
66. Katz E., Lareef M.H., Rassa J.C., Grande S.M., King L.B., Russo J., Ross S.R., Monroe J.G. MMTV Env encodes an ITAM responsible for transformation of mammary epithelial cells in three-dimensional culture. J. Exp. Med. 2005, 201:431-439.
67. Lu J., Lin W.-H., Chen S.-Y., Longnecker R., Tsai S.-C., Chen C.-L., Tsai C.-H. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J. Biol. Chem. 2006, 281:8806-8814.
68. Fotheringham J.A., Coalson N.E., Raab-Traub N. Epstein-Barr virus latent membrane protein-2A induces ITAM/Syk- and Akt-dependent epithelial migration through αV-integrin membrane translocation. J. Virol. 2012, 86:10308-10320.
69. Katz E., Dubois-Marshall S., Sims A.H., Faratian D., Li J., Smith E.S., Quinn J.A., Edward M., Meehan R.R., Evans E.E., Langdon S.P., Harrison D.J. A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br. J. Cancer 2010, 103:401-410.
70. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
71. Lowe S.W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004, 432:307-315.
72. Zhang J., Benavente C.A., McEvoy J., Flores-Otero2 J., Ding L., Chen X., Ulyanov A., Wu G., Wilson M., Wang J., Brennan R., Rusch M., Manning A.L., Ma J., Easton J., Shurtleff S., Mullighan C., Pounds S., Mukatira S., Gupta P., Neale G., Zhao D., Lu C., Fulton R.S., Fulton L.L., Hong X., Dooling D.J., Ochoa K., Naeve C., Dyson N.J., Mardis E.R., Bahrami A., Ellison D., Wilson R.K., Downing J., Dyer M.A. A Novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012, 481:329-334.
73. Prinos P., Garneau D., Lucier J.-F., Gendron D., Couture S., Boivin M., Brosseau1 J.-P., Lapointe E., Thibault P., Durand M., Tremblay K., Gervais-Bird J., Nwilati H., Klinck R., Chabot B., Perreault J.-P., Wellinger R.J., Elela S.A. Alternative splicing of SYK regulates mitosis and cell survival. Nat. Struct. Mol. Biol. 2011, 18:673-679.
74. Udyavar A.R., Hoeksema M.D., Clark J.E., Zou Y., Tang Z., Li Z., Li M., Chen H., Statnikov A., Shyr Y., Liebler D.C., Field J., Eisenberg R., Estrada L., Massion P.P., Quaranta V. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. BMC Syst. Biol. 2013, 7(Suppl. 5):S1.
75. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jané-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2013, 483:603-607.
76. Luangdilok S., Box C., Patterson L., Court W., Harrington K., Pitkin L., Rhys-Evans P., O-charoenrat P., Eccles S. Syk tyrosine kinase is linked to cell motility and progressin in squamous cell carcinomas of the head and neck. Cancer Res. 2007, 67:7907-7916.
77. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
78. Beitz L.O., Fruman D.A., Kurosaki T., Cantley L.C., Scharenberg A.M. Syk is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J. Biol. Chem. 1999, 274:32662-32666.
79. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
80. Srinivasan L., Sasaki Y., Calado D.P., Zhang B., Paik J.H., DePinho R.A., Kutok J.L., Kearney J.F., Otipoby K.L., Rajewsky K. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009, 139:573-586.
81. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
82. Longo P., Laurenti L., Gobessi S. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008, 111:846-855.
83. Inuzuka H., Fukushima H., Shaik S., Liu P. Mcl-1 ubiquitination and destruction. Oncotarget 2011, 2:239-244.
84. Inohara N., Ding L., Chen S., Núñez G. Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J. 1997, 16:1686-1694.
85. Portis T., Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 2004, 23:8619-8628.
86. Bieging K.T., Swanson-Mungerson M., Amick A.C., Longnecker R. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A. Cell Cycle 2010, 9:901-908.
87. Holcki M., Korneluk R.G. XIAP, the guardian angel. Nat. Rev. Mol. Cell Biol. 2001, 2:550-556.
88. Mamane Y., Petroulakis E., LeBacquer O., Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006, 25:6416-6422.
89. Carnevale J., Ross L., Puissant A., Banerji V. SYK regulates mTOR signaling in AML. Leukemia 2013, 27:2118-2128.
90. Psathas J.N., Doonan P.J., Raman P., Freedman B.D., Minn A.J., Thomas-Tikhonenko A. The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood 2013, 122:4220-4229.
91. Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr. Opin. Immunol. 2005, 17:290-297.
92. Wang W.-H., Childress M.O., Geahlen R.L. Syk interacts with and phosphorylates nucleolin to stabilize Bcl-xL mRNA and promote cell survival. Mol. Cell. Biol. 2014, 34:3788-3799.
93. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
94. Kanie T., Abe A., Matsuda T., Kuno Y., Towatari M., Yamamoto T., Saito H., Emi N., Naoe T. TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways. Leukemia 2004, 18:548-555.
95. Uckun F.M., Qazi S., Ma H., Tuel-Ahlgren L., Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2902-2907.
96. Goodman P.A., Wood C.M., Vassilev A., Mao C., Uckun F.M. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia. Oncogene 2001, 20:3969-3978.
97. Coopman P.J., Do M.T., Barth M., Bowden E.T., Hayes A.J., Basyuk E., Blancato J.K., Vezza P.R., McLeskey S.W., Mangeat P.H., Mueller S.C. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000, 406:742-747.
98. Moroni M., Soldatenkov V., Zhang L., Zhang Y., Stoica G., Gehan E., Rashidi B., Singh B., Ozdemirli M., Mueller S.C. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res. 2004, 64:7346-7354.
99. Toyama T., Iwase H., Yamashita H., Hara Y., Omoto Y., Sugiura H., Zhang Z., Fujii Y. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett. 2003, 189:97-102.
100. Yuan Y., Mendez R., Sahin A., Dai J.L. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res. 2001, 61:5558-5561.
101. Layton T., Stalens C., Gunderson F., Goodison S., Silletti S. Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion. Am. J. Pathol. 2009, 175:2625-2636.
102. Kunze E., Wendt M., Schlott T. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas. Int. J. Mol. Med. 2006, 18:547-557.
103. Yang Z., Huo L., Chen H., Ni B., Xiang J., Kang L., Wang L., Peng J., Yuan Y., Wang J. Hypermethylation and prognostic implication of Syk gene in human colorectal cancer. Med. Oncol. 2013, 30:586.
104. Hoeller C., Thallinger C., Pratscher B., Bister M.D., Schicher N., Loewe R., Heere-Ress E., Roka F., Sexl V., Pehamberger H. The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J. Invest. Dermatol. 2005, 124:1293-1299.
105. Muthusamy V., Duraisamy S., Bradbury C.M., Hobbs C., Curley D.P., Nelson B., Bosenberg M. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006, 66:11187-11193.
106. Wang S., Ding Y.-B., Chen G.-Y., Xia J.-G., Wu Z.-Y. Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma. World J. Gastroenterol. 2004, 10:1815-1818.
107. Nakashima H., Natsugoe S., Ishigami S., Okumura H., Matsumoto M., Hokita S., Aikou T. Clinical significance of nuclear expression of spleen tyrosine kinase (Syk) in gastric cancer. Cancer Lett. 2006, 236:89-94.
108. Jin Q., Liu C., Yan C., Tao B., Li Z., Cai Z. 5-aza-CdR induces the demethylation of Syk promoter in nasopharyngeal carcinoma cell. Gene 2012, 511:224-226.
109. Yuan Y., Wang J., Li J., Wang L., Li M., Yang Z., Zhang C., Dai J.L. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin. Cancer Res. 2006, 12:6687-6695.
110. Hong J., Hu K., Yuan Y., Sang Y., Bu Q., Chen G., Yang L., Li B., Huang P., Chen D., Liang Y., Zhang R., Pan J., Zeng Y.-X., Kang T. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J. Clin. Invest. 2012, 122:2165-2175.
111. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
112. Taube J.H., Herschkowitz J.I., Komurov K., Zhou A.Y., Gupta S., Yang J., Hartwell K., Onder T.T., Gupta P.B., Evans K.W., Hollier B.G., Ram P.T., Lander E.S., Rosen J.M., Weinberg R.A., Mania S.A. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107. (19132-19132).
113. Zhang X., Shrikhande U., Zhou Q., Geahlen R.L. A role for the protein-tyrosine kinase, Syk, in regulating cell-cell adhesion and motility in breast cancer cells. Mol. Cancer Res. 2009, 7:634-644.
114. Larive R.M., Urbach S., Poncet J., Jouin P., Mascré G., Sahuquet A., Mangeat P.H., Coopman P.J., Bettache N. Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion. Oncogene 2009, 28:2337-2347.
115. Krisenko M.O., Cartagena A., Raman A., Geahlen R.L. Nanomechanical property maps of breast cancer cells as determined by multiharmonic atomic force microscopy reveal Syk-dependent changes in microtubule stability mediated by MAP1B. Biochemistry 2014, (in press).
116. Maruyama S., Kurosaki T., Sada K., Yamanashi Y., Yamamoto T., Yamamura H. Physical and functional association of cortactin with Syk in human leukemic cell line K562. J. Biol. Chem. 1996, 271:6631-6635.
117. Peters J.D., Furlong M.T., Asai D.J., Harrison M.L., Geahlen R.L. Syk, activated by cross-linking the B-cell antigen receptor, localizes to the cytosol where it interacts with and phosphorylates α-tubulin on tyrosine. J. Biol. Chem. 1996, 271:4755-4762.
118. Zyss D., Montcourrier P., Vidal B., Anguille C., Mérezègue F., Sahuquet A., Mangeat P.H., Coopman P.J. The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression. Cancer Res. 2005, 65:10872-10880.
119. Xue L., Wang W.-H., Iliuk A., Hu L., Galan J.A., Yu S., Hans M., Geahlen R.L., Tao W.A. Sensitive kinase assay linked with phosphoproteomics for identifying direct kinase substrates. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:5615-5620.
120. Wang L., Duke L., Zhang P. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 2003, 63:4724-4730.
121. Latour S., Chow L.M.L., Veillette A. Differential intrinsic enzymatic activity of Syk and Zap-70 protein-tyrosine kinases. J. Biol. Chem. 1996, 271:22782-22790.
122. Hong J., Yuan Y., Wang J., Liao Y., Zou R., Zhu C., Li B., Liang Y., Huang P., Wang Z., Lin W., Zeng Y., Dai J.L., Chung R.T. Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma. Cancer Res. 2014, 74:1845-1856.
123. Wang L., Devarajan E., He J., Reddy S.P., Dai J.L. Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res. 2005, 65:10289-10297.
124. Zhou F., Hu J., Ma H., Harrison M.L., Geahlen R.L. Nucleocytoplasmic trafficking of the Syk protein-tyrosine kinase. Mol. Cell. Biol. 2006, 26:3478-3491.